Wuxi Biologics Placement - In Time for the Next Lock-Up, Returns Will Probably Not Match Prior Ones
WuXi Biologics (Cayman) Inc. (2269 HK) plans to raise around US$600m through a mix of primary (85%) and secondary (15%) offering. This will be the...
311 Views
"Exchange Arbitrage" For Early-Stage Biotech!
Hong Kong Exchanges and Clearing Limited (HKEX) has decided to modify its rules to allow "pre-commercial" biopharmaceutical (aka biotechnology)...
520 Views
2017 HK IPOs Analytics: Good Deals Don't Need Cornerstones
Since we published our first annual HK IPO analysis (5 Key Charts to Wrap-Up 2015 HK IPO - Broker, Sector, and Retail Analytics) in Feb 2015, it...
403 Views
Wuxi Biologics Placement - Selldown Right when Lockup Expires Suggests Eagerness to Offload
Wuxi Biologics Holdings is selling about US$551m worth of WuXi Biologics (Cayman) Inc. (2269 HK) shares. Post share sale, Wuxi Biologics Holdings...
418 Views
Valuation of Celltrion + Celltrion Healthcare Is Not as Expensive as Samsung Biologics
Celltrion Healthcare (091990 KS) (CH) is raising US$701 - 884m in its upcoming IPO. Proceeds raised will be used to fund general working capital,...
301 Views